The company's chief financial officer Vikas Sinha will also leave the company to pursue opportunities.
Management Changes
A CNBC report suggested that the board lost confidence in both Hallal and Sinha although it is unclear why.
Remaining Risks
In a brief research report on Monday Heather Behanna of Wedbush noted that Alexion's audit and finance Committee announcement that it has not yet identified any facts that would require an update to its prior financial results could be seen as a "positive" — especially since eculizumab generates more than 90 percent of the company's top-line revenues.
Accordingly, the analyst believes that there will be no revenue adjustment, which in turn has no affect on her prior stock rating of Neutral and $135 price target.
Behanna reiterated that prior risks on the stocks remain in place, including:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.